Some dilution? I posit there will be a lot more than "some".
Look at the math. The company is likely to need at least $20M to continue operations, finance the Brilacidin Phase 2 ABSSSI trials and the Phase 1 oral mucositis trials and continue paying its lavish salaries. Even at $.10/share and with a 1:6 RS, and even assuming the stock doesn't drop more pre/post split, they would need to sell 33M shares. After a 1:6 RS but before selling new shares, they would have 106M/6 = 17.6M shares outstanding.
So essentially, all existing shares would be diluted by a factor of almost 3. And that assumes the stock maintains the $.10/$.60 pre/post-split price. If it doesn't, they would likely have to try to sell even more shares.
